United States: Reverse Payments, Actavis, and the Lower Courts at Sea, Part 2: The Brewing Conflict Over Non-Cash Settlements

Our first post in this series was titled "What Is a Reverse Payment?" As the recent cases discussed in today's post show, the courts are struggling with a fundamental component of that question: What, for that matter, is a payment?

Among the issues left unresolved by the Supreme Court's Actavis opinion is the question of whether a reverse payment settlement can run afoul of antitrust laws when no actual cash changes hands. Instead, these arrangements might include a promise by the brand name manufacturer to delay the introduction of an authorized generic, a settlement of unrelated litigation on terms beneficial to the generic manufacturer, or a licensing agreement whereby the generic manufacturer gains rights to market the brand name product overseas. These can be of tremendous value to the generic manufacturer, but they are different from the "pay[ment of] many millions of dollars" that was the focus of Justice Breyer's opinion for the Actavis majority.

According to the FTC, the potentially anticompetitive effect of these settlements is no different: in return for some form of consideration, the generic manufacturer agrees to delay its entry of a product that would drive down prices paid by consumers. But the Actavis Court did not state explicitly whether non-cash settlements are included in its holding, and the district courts that have struggled with the question—including three in the past month alone—have reached inconsistent results.

The "'Payment' Means Cash" Opinions

On one side are the judges who note that both the majority and the dissenting opinions in Actavis "reek with discussion of payment of money." The first of these, Judge Walls of the District of New Jersey, acknowledged this past January in the Lamictal[1] litigation that a non-monetary settlement is at least "within the gestalt of Actavis." However, because both the facts in Actavis and the words in its opinions revolved around cash payments, he concluded that "good jurisprudence" counseled him not to "extend the holding of Actavis to . . . non-monetary facts."

The FTC, a strident opponent of reverse payment settlements, filed an amicus brief with the Third Circuit urging reversal of the Lamictal decision. Oral argument on the appeal will likely take place in late 2014 or early 2015.

The District of Rhode Island recently followed Judge Walls' lead in the Loestrin 24[2] case, characterizing the Supreme Court's focus on cash payments as a "fixation." It also noted that the factors the Actavis Court instructed lower courts to use in evaluating reverse payment settlements all require an assessment of the value of the consideration in the context of the facts of the settlement. A non-cash settlement "is almost impossible to measure" against those factors. The court went on to say that it was loath to extend Actavis beyond its facts and language, since that case already represents such a "significant change in direction."

The Rhode Island court explained that it was not without "reservations" about the holding and that its decision was a "close call." Echoing Chief Justice Roberts' dissenting opinion, the court bemoaned the difficulty created for lower courts by the Actavis decision.

The "Non-Monetary Payments are Payments Too" Opinions

By sheer numbers, the "payment means cash" opinions are in the slight minority at this early stage. Courts for the District of Massachusetts and the Eastern District of Pennsylvania, along with Judge Walls' colleague, Judge Sheridan of the District of New Jersey, have issued opinions stating that Actavis is not limited to cases involving monetary payments. Two of those decisions, in the Niaspan[3] and Lipitor[4] cases, relied on the broad gloss given to the word "payment" by Black's Law Dictionary and court opinions from other contexts.

Meanwhile, these courts point out that nowhere in the Actavis decision did the Court exclude non-monetary settlements from its reach; indeed, the Lipitor court noted, "it is clear that the Supreme Court focuses on the antitrust intent of the settling parties rather than the manner of payment." Furthermore, in litigation relating to the acid reflux drug Nexium[5] the District of Massachusetts suggested that to restrict the Actavis holding to monetary payments would fail to align the law with "modern-day realities," citing the FTC's statements that non-monetary settlements are just as much a part of the perceived "pay-for-delay" scourge as cash payments.

A Heavy Burden

Still, the plaintiff's road in a case involving non-monetary settlements will not be an easy one, even in a district where such settlements are recognized as falling under Actavis. The Lipitor court, despite finding that non-cash settlements can trigger antitrust liability, dismissed the complaint with prejudice. It found that the plaintiffs had failed to satisfy the "plausibility" pleading requirement imposed by Iqbal and Twombly, as overlain on the new Actavis regime. The court reasoned that a complaint must provide a reliable estimate of the monetary value of the non-monetary settlement in order to engage in the proportionality analysis—i.e. the question of whether the settlement amount is too "large"—required by Actavis. Since plaintiffs had not attempted to provide such an estimate, the complaint had to be dismissed.

Diligent plaintiffs will have to include in their pleadings some reasonably compelling methodology by which to value non-monetary reverse payment settlements. That is, assuming such settlements are found by the appellate courts to fall under Actavis at all. Stay tuned.


>

[1] In re Lamictal Direct Purchaser Antitrust Litig., No. 12-cv-995, 2014 U.S. Dist. LEXIS 9257 (D.N.J. Jan. 24, 2014). The settlement at issue in the Lamictal litigation provided the generic manufacturer with the assurance, essentially, that when its products came to market they would not face competition from the brand manufacturer's authorized generic for a certain period of time.

[2] In re Loestrin 24 FE Antitrust Litig., No. 13-md-2472, 2014 U.S. Dist. LEXIS 123322 (D.R.I. Sept. 4, 2014). The settlements at issue in Loestrin 24 included promises by the brand manufacturer to delay launch of an authorized generic and not to license other generics for a certain period; a grant of licensing rights for branded products to the generic manufacturer; and licenses and co-promotion agreements with respect to branded drugs that were unrelated to the underlying patent litigation.

[3] In re Niaspan Antitrust Litig., No. 13-md-2460, 2014 U.S. Dist. LEXIS 124818 (E.D. Pa. Sept. 5, 2014). In Niaspan, the disputed settlement included a delay of authorized generics; a royalty payment to the generic manufacturer for sales of Niaspan and a separate drug; a co-promotion agreement; and a cash payment that was ostensibly made in exchange for the generic manufacturer's agreement to develop manufacturing processes for Niaspan and another drug, and to act as a back-up supplier for those products.

[4] In re Lipitor Antitrust Litig., No. 12-cv-02389, 2014 U.S. Dist. LEXIS 127877 (D.N.J. Sept. 12, 2014). The settlement agreement at issue in the Lipitor case included the settlement of overseas litigation and litigation concerning a separate product on terms that the antitrust plaintiffs claimed were so forgiving to the generic manufacturer as to constitute a "sweetheart" deal. The generic manufacturer was also awarded overseas licensing rights to the disputed product.

[5] In re Nexium (Esomeprazole) Antitrust Litig., 968 F. Supp. 2d 367 (D. Mass. 2013). In relevant part, the settlement at issue in the Nexium case involved a "no authorized generic" promise by the brand name manufacturer.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Emails

From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.